{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:05:39Z","timestamp":1793379939419,"version":"4.5.0"},"reference-count":46,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,6]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Cancer vaccines are emerging as promising therapies to not only prevent cancer but to treat cancer. Here, we developed a therapeutic vaccine for multiple myeloma (MM) using B-cell maturation antigen (BCMA) protein as a target. Given the remarkable efficacy of COVID-19 messenger RNA (mRNA) vaccines, we first packaged sequence- and base-optimized BCMA mRNA into lipid nanoparticles (LNPs) using next-generation ionizable lipid, enhancing their accumulation in the spleen. A toll-like receptor 3 agonist, polyinosinic:polycytidylic acid [poly(I:C)], was also encapsulated in LNPs to further elicit BCMA-specific immune response. BCMA-mRNA LNPs were internalized by dendritic cells (DCs) in vitro, triggering proliferation and activation of BCMA-specific CD8+ cytolytic T cells (CTLs). Importantly, these CTLs lysed BCMA+ U266 MM cells and CD138+ patient MM cells, without affecting BCMA-knockout U266 or CD138\u2212 patient\u2013derived bone marrow cells. Vaccination of C57BL\/6J mice with BCMA-mRNA LNPs activated splenic DCs and induced BCMA-specific CTLs, assessed by tetramer staining, which selectively killed murine 5TGM1 BCMA overexpressing MM cells. Finally, vaccination of C57BL\/KaLwRijHsd mice bearing BCMA-overexpressing 5TGM1 cells inhibited tumor growth associated with BCMA-specific CD8+ T-cell responses. The combination treatment with poly(I:C) further triggered the immune response induced by BCMA-mRNA LNPs in all instances. Our findings provide the framework for clinical evaluation of BCMA-mRNA LNP vaccines to improve patient outcome in MM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025028597","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T18:19:47Z","timestamp":1753294787000},"page":"2322-2335","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma"],"prefix":"10.1182","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0235-4649","authenticated-orcid":false,"given":"Debasmita","family":"Dutta","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiye","family":"Liu","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Wen","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0652-2905","authenticated-orcid":false,"given":"Arghya","family":"Ray","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9241-0768","authenticated-orcid":false,"given":"Alessandro","family":"Salatino","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangdong","family":"Liu","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Gulla","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia, Istituto di Ricovero e Cura a Carattere Scientifico, Candiolo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teru","family":"Hideshima","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6729-2672","authenticated-orcid":false,"given":"Yan","family":"Song","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6418-0886","authenticated-orcid":false,"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"11","key":"2025110611212441100_bib1","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"2025110611212441100_bib2","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/s43018-022-00418-6","article-title":"Cancer vaccines: the next immunotherapy frontier","volume":"3","author":"Lin","year":"2022","journal-title":"Nat Cancer"},{"issue":"1","key":"2025110611212441100_bib3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41392-023-01579-1","article-title":"mRNA vaccines in disease prevention and treatment","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"7607","key":"2025110611212441100_bib4","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"issue":"1","key":"2025110611212441100_bib5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13045-022-01247-x","article-title":"Cancer vaccines as promising immuno-therapeutics: platforms and current progress","volume":"15","author":"Liu","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2025110611212441100_bib6","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41408-024-01191-8","article-title":"CAR-T cell therapy in multiple myeloma: current status and future challenges","volume":"14","author":"Swan","year":"2024","journal-title":"Blood Cancer J"},{"issue":"5","key":"2025110611212441100_bib7","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","article-title":"From concept to cure: the evolution of CAR-T cell therapy","volume":"33","author":"Patel","year":"2025","journal-title":"Mol Ther"},{"issue":"9","key":"2025110611212441100_bib8","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrclinonc.2014.111","article-title":"Therapeutic vaccines for cancer: an overview of clinical trials","volume":"11","author":"Melero","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"2025110611212441100_bib9","doi-asserted-by":"crossref","first-page":"103505","DOI":"10.1016\/j.drudis.2023.103505","article-title":"Design of lipid-based nanoparticles for delivery of therapeutic nucleic acids","volume":"28","author":"Mendon\u00e7a","year":"2023","journal-title":"Drug Discov Today"},{"issue":"12","key":"2025110611212441100_bib10","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat Rev Mater"},{"issue":"8","key":"2025110611212441100_bib11","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41571-024-00913-y","article-title":"Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins","volume":"21","author":"Neri","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2025110611212441100_bib12","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12967-022-03285-y","article-title":"B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages","volume":"20","author":"Nobari","year":"2022","journal-title":"J Transl Med"},{"issue":"4","key":"2025110611212441100_bib13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/14737140.2019.1586539","article-title":"Anti-BCMA antibodies in the future management of multiple myeloma","volume":"19","author":"Gavriatopoulou","year":"2019","journal-title":"Expert Rev Anticancer Ther"},{"issue":"9","key":"2025110611212441100_bib14","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"issue":"10","key":"2025110611212441100_bib15","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1073\/pnas.1821733116","article-title":"Anti-BCMA immunotoxins produce durable complete remissions in two mouse myeloma models","volume":"116","author":"Shancer","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2025110611212441100_bib16","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.matt.2022.03.006","article-title":"The roles of polymers in mRNA delivery","volume":"5","author":"Huang","year":"2022","journal-title":"Matter"},{"issue":"12","key":"2025110611212441100_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/marc.202270036","article-title":"Effective mRNA protection by poly(l-ornithine) synergizes with endosomal escape functionality of a charge-conversion polymer toward maximizing mRNA introduction efficiency","volume":"43","author":"Dirisala","year":"2022","journal-title":"Macromol Rapid Commun"},{"issue":"April","key":"2025110611212441100_bib18","doi-asserted-by":"crossref","first-page":"16010","DOI":"10.1038\/npjvaccines.2016.10","article-title":"Intradermal immunisation using the TLR3-ligand Poly (I:C) as adjuvant induces mucosal antibody responses and protects against genital HSV-2 infection","volume":"1","author":"Bardel","year":"2016","journal-title":"NPJ Vaccines"},{"issue":"3","key":"2025110611212441100_bib19","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41587-023-01774-z","article-title":"A microneedle vaccine printer for thermostable COVID-19 mRNA vaccines","volume":"42","author":"vander Straeten","year":"2024","journal-title":"Nat Biotechnol"},{"issue":"January","key":"2025110611212441100_bib20","first-page":"1","article-title":"A novel defined TLR3 agonist as an effective vaccine adjuvant","volume":"14","author":"Ko","year":"2023","journal-title":"Front Immunol"},{"issue":"33","key":"2025110611212441100_bib21","doi-asserted-by":"crossref","first-page":"e2303576","DOI":"10.1002\/advs.202303576","article-title":"Hybrid LNP prime dendritic cells for nucleotide delivery","volume":"10","author":"Das","year":"2023","journal-title":"Adv Sci"},{"issue":"5","key":"2025110611212441100_bib22","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1158\/2643-3230.BCD-21-0047","article-title":"Bortezomib induces anti-multiple myeloma immune response mediated by cGAS\/STING pathway activation","volume":"2","author":"Gulla","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"3","key":"2025110611212441100_bib23","doi-asserted-by":"crossref","first-page":"e2205532","DOI":"10.1002\/advs.202205532","article-title":"Lipid nanoparticle delivery system for mRNA encoding B7H3-redirected bispecific antibody displays potent antitumor effects on malignant tumors","volume":"10","author":"Huang","year":"2023","journal-title":"Adv Sci"},{"issue":"8","key":"2025110611212441100_bib24","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1038\/s41591-021-01387-6","article-title":"Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2","volume":"27","author":"Au","year":"2021","journal-title":"Nat Med"},{"issue":"3","key":"2025110611212441100_bib25","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1158\/2767-9764.CRC-21-0157","article-title":"Allogeneic anti-BCMA CAR T cells are superior to multiple myeloma-derived CAR T cells in preclinical studies and may be combined with gamma secretase inhibitors","volume":"2","author":"Metelo","year":"2022","journal-title":"Cancer Res Commun"},{"issue":"1","key":"2025110611212441100_bib26","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/s41467-024-45561-z","article-title":"Epigenetic regulation of CD38\/CD48 by KDM6A mediates NK cell response in multiple myeloma","volume":"15","author":"Liu","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"2025110611212441100_bib27","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s11095-022-03445-1","article-title":"Lipid microparticles show similar efficacy with lipid nanoparticles in delivering mRNA and preventing cancer","volume":"40","author":"Ji","year":"2023","journal-title":"Pharm Res"},{"key":"2025110611212441100_bib28","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1038\/srep02534","article-title":"Ligand modified nanoparticles increases cell uptake, alters endocytosis and elevates glioma distribution and internalization","volume":"3","author":"Gao","year":"2013","journal-title":"Sci Rep"},{"issue":"3","key":"2025110611212441100_bib29","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1021\/acs.nanolett.6b03329","article-title":"Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy","volume":"17","author":"Oberli","year":"2017","journal-title":"Nano Lett"},{"issue":"7","key":"2025110611212441100_bib30","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/s41375-020-0705-4","article-title":"BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications","volume":"34","author":"Bae","year":"2020","journal-title":"Leukemia"},{"issue":"6","key":"2025110611212441100_bib31","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","article-title":"A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates","volume":"26","author":"Sabnis","year":"2018","journal-title":"Mol Ther"},{"issue":"1","key":"2025110611212441100_bib32","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41596-022-00755-x","article-title":"Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery","volume":"18","author":"Wang","year":"2023","journal-title":"Nat Protoc"},{"key":"2025110611212441100_bib33","doi-asserted-by":"crossref","first-page":"114416","DOI":"10.1016\/j.addr.2022.114416","article-title":"The role of lipid components in lipid nanoparticles for vaccines and gene therapy","volume":"188","author":"Hald Albertsen","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"2025110611212441100_bib34","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4155\/tde-2016-0006","article-title":"mRNA vaccine delivery using lipid nanoparticles","volume":"7","author":"Reichmuth","year":"2016","journal-title":"Ther Deliv"},{"issue":"1","key":"2025110611212441100_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neo.2021.11.009","article-title":"Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition","volume":"24","author":"Bennett","year":"2022","journal-title":"Neoplasia"},{"issue":"7662","key":"2025110611212441100_bib36","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"issue":"7662","key":"2025110611212441100_bib37","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"2025110611212441100_bib38","unstructured":"Merck & Co., Inc\n          . Moderna and Merck announce mRNA-4157\/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA (pembrolizumab), was granted breakthrough therapy designation by the FDA for adjuvant treatment of patients with high-risk melanoma following complete resection. 22 February 2023. Accessed 17 July 2024. https:\/\/www.merck.com\/news\/moderna-and-merck-announce-mrna-4157-v940-an-investigational-personalized-mrna-cancer-vaccine-in-combination-with-keytruda-pembrolizumab-was-granted-breakthrough-therapy-designation-by-the\/."},{"issue":"7823","key":"2025110611212441100_bib39","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"issue":"9","key":"2025110611212441100_bib40","doi-asserted-by":"crossref","first-page":"e1629259","DOI":"10.1080\/2162402X.2019.1629259","article-title":"HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory","volume":"8","author":"Grunwitz","year":"2019","journal-title":"Oncoimmunology"},{"key":"2025110611212441100_bib41","unstructured":"Major agreement to deliver new cancer vaccine trials. Accessed 28 July 2020. https:\/\/www.gov.uk\/government\/news\/major-agreement-to-deliver-new-cancer-vaccine-trials."},{"issue":"7963","key":"2025110611212441100_bib42","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"issue":"11","key":"2025110611212441100_bib43","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1038\/s41591-022-02061-1","article-title":"The landscape of mRNA nanomedicine","volume":"28","author":"Huang","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"2025110611212441100_bib44","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41698-023-00364-1","article-title":"Applications and clinical trial landscape using toll-like receptor agonists to reduce the toll of cancer","volume":"7","author":"Rolfo","year":"2023","journal-title":"NPJ Precis Oncol"},{"issue":"6","key":"2025110611212441100_bib45","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","article-title":"The clinical progress of mRNA vaccines and immunotherapies","volume":"40","author":"Barbier","year":"2022","journal-title":"Nat Biotechnol"},{"issue":"4","key":"2025110611212441100_bib46","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.vaccine.2008.11.013","article-title":"The TLR3 agonist poly(I:C) targets CD8+ T cells and augments their antigen-specific responses upon their adoptive transfer into na\u00efve recipient mice","volume":"27","author":"Salem","year":"2009","journal-title":"Vaccine"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/19\/2322\/2419254\/blood_bld-2025-028597-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/19\/2322\/2419254\/blood_bld-2025-028597-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T16:21:31Z","timestamp":1762446091000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/146\/19\/2322\/546316\/A-BCMA-mRNA-vaccine-is-a-promising-therapeutic-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":46,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2025,11,6]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025028597","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,6]]},"published":{"date-parts":[[2025,11,6]]}}}